Phenprobamate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Phenprobamate is a skeletal muscle relaxant indicated in the treatment of pain caused by muscle spasms.

Generic Name
Phenprobamate
DrugBank Accession Number
DB13354
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 179.219
Monoisotopic: 179.094628663
Chemical Formula
C10H13NO2
Synonyms
  • Phenprobamate
External IDs
  • MH-532

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Phenprobamate.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Phenprobamate.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Phenprobamate.
AclidiniumPhenprobamate may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenprobamate.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Phenprobamate.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Phenprobamate.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Phenprobamate.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Phenprobamate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Phenprobamate.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
KUIFLEX 200 MG/200 MG FİLM TABLET, 40 ADETPhenprobamate (200 mg) + Acetaminophen (200 mg)Tablet, film coatedOralABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
KUILIL 200 MG/ 200 MG FILM KAPLI TABLET, 40 TABLETPhenprobamate (200 mg) + Acetaminophen (200 mg)Tablet, film coatedOralEXELTIS İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
M03BA71 — Phenprobamate, combinations with psycholepticsM03BA51 — Phenprobamate, combinations excl. psycholepticsM03BA01 — Phenprobamate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Carboximidic acids and derivatives / Organopnictogen compounds / Organooxygen compounds / Imines / Hydrocarbon derivatives
Substituents
Aromatic homomonocyclic compound / Carboximidic acid derivative / Hydrocarbon derivative / Imine / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
UJZ473TPS0
CAS number
673-31-4
InChI Key
CAMYKONBWHRPDD-UHFFFAOYSA-N
InChI
InChI=1S/C10H13NO2/c11-10(12)13-8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H2,11,12)
IUPAC Name
3-phenylpropyl carbamate
SMILES
NC(=O)OCCCC1=CC=CC=C1

References

General References
  1. TITCK Product Information: Gamaflex (phenprobamate) oral tablet [Link]
  2. TITCK Product Information: Kuiflex (phenprobamate/acetaminophen) oral tablets [Link]
ChemSpider
4606
BindingDB
66801
ChEBI
31992
ChEMBL
CHEMBL1079576
ZINC
ZINC000001676954
Wikipedia
Phenprobamate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coatedOral400 mg
Tablet, film coatedOral400 mg
Tablet, film coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.514 mg/mLALOGPS
logP1.77ALOGPS
logP2.05ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)15.69ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.32 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity50.06 m3·mol-1ChemAxon
Polarizability19.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 23, 2017 20:40 / Updated on June 02, 2021 20:04